Cipla
Prateek Sharma is a seasoned professional with extensive experience in mergers and acquisitions within the healthcare sector. Currently serving as the Director and Head of Global Corporate M&A at Cipla since December 2022, Prateek previously held the role of Associate Director focusing on Corporate Venture Capital and M&A. Prior to this, a brief tenure as Head of Mergers & Acquisitions and Corporate Development at MEDGENOME provided valuable insights into strategic decision-making. Before returning to Cipla in June 2018 as Associate Director and Executive Assistant to the Global CEO, Prateek led various projects, including the establishment of a diagnostics business and driving product leadership. Earlier in the career, roles at Goldman Sachs and MSCI Inc contributed to expertise in financial analysis and investment strategies. Prateek holds an MBA in Finance from the Indian School of Business and is a CFA Charterholder.
This person is not in any teams
This person is not in any offices
Cipla
19 followers
Cipla is a pharmaceutical company. The Company's strategic business units include Active Pharmaceutical Ingredients (APIs), Respiratory and Cipla Global Access. The Company's geographical segments include India, USA, South Africa and Rest of the World. The Company manufactures metered dose inhalers, dry powder inhalers, nasal sprays, nebulizers and a range of inhaled accessory devices. Cipla Global Access is a tender-based institutional business that concentrates on approximately four therapy areas: human immunodeficiency virus/acquired immuno deficiency syndrome (HIV/AIDS), malaria, multi drug-resistant tuberculosis and reproductive health. The Company offers its products for the therapeutic areas, including cardiovascular, children's health, dermatology and cosmetology, diabetes, HIV/AIDS, infectious diseases and critical care, malaria, neurosciences, oncology, ophthalmology, osteoporosis, respiratory, urology and women's health.